These findings systematically demonstrate that fraxin mitigates NAFLD through the “gut-liver axis” cycle, and its pharmacological mechanism may be associated with suppressed FAT/CD36 gene expression. This evidence concerns the gene CD36 and metabolic dysfunction-associated steatotic liver disease.